0001172661-11-000307.txt : 20110510
0001172661-11-000307.hdr.sgml : 20110510
20110510172250
ACCESSION NUMBER: 0001172661-11-000307
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20110510
DATE AS OF CHANGE: 20110510
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: ANADYS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001128495
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 223193172
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-79854
FILM NUMBER: 11829349
BUSINESS ADDRESS:
STREET 1: 5871 OBERLIN DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8585303600
MAIL ADDRESS:
STREET 1: 5871 OBERLIN DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC
CENTRAL INDEX KEY: 0001055951
IRS NUMBER: 133976876
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: SC 13G/A
BUSINESS ADDRESS:
STREET 1: 767 3RD AVENUE
STREET 2: 30TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
BUSINESS PHONE: 2126845700
MAIL ADDRESS:
STREET 1: 767 3RD AVENUE
STREET 2: 30TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10017
SC 13G/A
1
anadys0511a3.txt
SCHEDULE 13G HOLDINGS REPORT AMENDMENT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
Amendment No. 3
Anadys Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
03252Q408
(CUSIP Number)
April 1, 2011
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[x] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
CUSIP No. 03252Q408
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
OrbiMed Advisors LLC
2. Check the Appropriate Box if a Member Of a Group (See Instructions)
[ ] (a)
[ ] (b)
3. SEC Use Only
4. Citizenship or Place of Organization
Delaware
5. Sole Voting Power: 0
Number of
Shares 6. Shared Voting Power: 1,999,900
Beneficially
Owned by 7. Sole Dispositive Power: 0
Each Reporting
Person With 8. Shared Dispositive Power: 1,999,900
9. Aggregate Amount Beneficially Owned by Each Reporting Person
1,999,900
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
11. Percent of Class Represented by Amount in Row (9) 3.48%
12. Type of Reporting Person (See Instructions) IA
CUSIP No. 03252Q408
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
OrbiMed Capital LLC
2. Check the Appropriate Box if a Member of a Group (See Instructions)
[ ] (a)
[ ] (b)
3. SEC Use Only
4. Citizenship or Place of Organization
Delaware
5. Sole Voting Power: 0
Number of
Shares 6. Shared Voting Power: 3,792,500
Beneficially
Owned by 7. Sole Dispositive Power: 0
Each Reporting
Person With 8. Shared Dispositive Power: 3,792,500
9. Aggregate Amount Beneficially Owned by Each Reporting Person
3,792,500
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
11. Percent of Class Represented by Amount in Row (9) 6.59%
12. Type of Reporting Person (See Instructions) IA
CUSIP No. 03252Q408
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Samuel D. Isaly
2. Check the Appropriate Box if a Member of a Group (See Instructions)
[ ] (a)
[ ] (b)
3. SEC Use Only
4. Citizenship or Place of Organization
United States
5. Sole Voting Power: 0
Number of
Shares 6. Shared Voting Power: 5,792,400
Beneficially
Owned by 7. Sole Dispositive Power: 0
Each Reporting
Person With 8. Shared Dispositive Power: 5,792,400
9. Aggregate Amount Beneficially Owned by Each Reporting Person:
5,792,400
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions)
11. Percent of Class Represented by Amount in Row (9) 10.07%
12. Type of Reporting Person (See Instructions) HC
Item 1. (a) Issuer: Anadys Pharmaceuticals, Inc.
1. Address:
5871 Oberlin Drive, Suite 200
San Diego, California 92121
Item 2. (a) Name of Person Filing:
OrbiMed Advisors LLC
OrbiMed Capital LLC
Samuel D. Isaly
(b) Address of Principal Business Offices:
767 Third Avenue, 30th Floor
New York, New York 10017
(c) Citizenship:
Please refer to Item 4 on each cover sheet for each filing person
(d) Title of Class of Securities
Common stock
(e) CUSIP Number: 03252Q408
Item 3. OrbiMed Advisors LLC and OrbiMed Capital LLC are investment advisors in
accordance with ss.240.13d-1(b)(1)(ii)(E). Samuel D. Isaly is a control person
in accordance with ss.240.13d-1(b)(1)(ii)(G).
Item 4. Ownership
Please see Items 5 - 9 and 11 for each cover sheet for each filing
separately
Item 5. Ownership of Five Percent or Less of a Class
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Reporting persons are holding 10.07% (3.48% in the case of
OrbiMed Advisors LLC and 6.59% in the case of OrbiMed Capital LLC) of
the securities on behalf of other persons who have the right to
receive or the power to direct the receipt of dividends from, or
proceeds from sale of, such securities. No one such other person's
interest in the securities whose ownership is reported here relates
to more than five percent of the class.
OrbiMed Advisors LLC and OrbiMed Capital LLC hold shares and share
equivalents issuable upon the conversion of warrants on
behalf of Stichting Depositary APG Developed Markets Equity Pool
(850,000 shares), Caduceus Capital Master Fund Limited (1,300,000
shares and 115,500 warrants), Caduceus Capital II, L.P. (945,000
shares and 109,900 warrants), UBS Eucalyptus Fund, L.L.C. (750,000
shares and 91,000 warrants), PW Eucalyptus Fund, Ltd. (50,000
shares and 9,100 warrants), Summer Street Life Sciences Hedge Fund
Investors, LLC (485,000 shares and 42,000 warrants), The Biotech
Growth Trust PLC (1,000,000 shares), Knightsbridge Netherlands II,
LP (13,500 shares), and Knightsbridge Netherlands III, LP (31,400
shares).
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and held in the ordinary
course of business and were not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Date: May 10, 2011
OrbiMed Advisors LLC
By: /s/ Samuel D. Isaly
---------------------------
Name: Samuel D. Isaly
Title: Managing Member
OrbiMed Capital LLC
By: /s/ Samuel D. Isaly
----------------------------
Name: Samuel D. Isaly
Title: Managing Member
By: /s/ Samuel D. Isaly
----------------------------
Name: Samuel D. Isaly
JOINT FILING AGREEMENT
The undersigned hereby agree that the Statement on this Schedule 13G/A dated
May 10, 2011, (the "Schedule 13G/A"), with respect to the common stock
par value $.001 per share, of Anadys Pharmaceuticals, Inc. is filed on
behalf of each of us pursuant to and in accordance with the provisions of
Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended,
and that this Agreement shall be included as an Exhibit to this Schedule
13G/A. Each of the undersigned agrees to be responsible for the timely filing
of the Schedule 13G/A, and for the completeness and accuracy of the
information concerning itself contained therein. This Agreement may be
executed in any number of counterparts, all of which taken together shall
constitute one and the same instrument.
IN WITNESS WHEREOF, the undersigned have executed this Agreement as of
the 10th day of May 2011.
OrbiMed Advisors LLC
By: /s/ Samuel D. Isaly
---------------------------
Name: Samuel D. Isaly
Title: Managing Member
OrbiMed Capital LLC
By: /s/ Samuel D. Isaly
----------------------------
Name: Samuel D. Isaly
Title: Managing Member
By: /s/ Samuel D. Isaly
----------------------------
Name: Samuel D. Isaly
Statement of Control Person
The Statement on this Schedule 13G/A dated May 10, 2011 with respect to
the common stock, $.001 par value per share, of Anadys Pharmaceuticals, Inc.
is filed by Samuel D. Isaly in accordance with the provisions of Rule
13d-1(b) and Rule 13d-1(k),respectively, as control person (HC) of OrbiMed
Advisors LLC and OrbiMed Capital LLC.
OrbiMed Advisors LLC and OrbiMed Capital LLC file this statement on Schedule
13G/A in accordance with the provisions of Rule 13d-1(b) and Rule 13d-1(k),
respectively, as investment advisors (IA).